Follistatin-344

Follistatin was first isolated from the ovary, where it suppresses follicle-stimulating hormone, FSH, the pituitary signal that drives egg development in women and sperm production in men. Its muscle role came later, when researchers found that it binds activin and myostatin, two members of the same signaling family.

That history explains both its promise and its risk. Follistatin is a binding protein that traps several related signals at once. Trap myostatin and muscle grows. Trap activin as well and reproductive hormones can shift, which is why its developers worried from the start about effects on the hypothalamic-pituitary-gonadal axis, the hormone chain that runs fertility.

It is also large. The form released from muscle in the gene therapy work is 315 amino acids long, while BPC-157, for comparison, has 15. Calling follistatin a peptide stretches the word; it is a full protein, with everything that implies for how it is made, stored and handled by the immune system.²¹³

Myostatin acts by docking onto activin type II receptors on muscle cells, mainly one called ActRIIB. In 2001 the Baltimore group showed that follistatin blocks that docking in the lab. They then built mice whose muscles overproduced follistatin. Independent lines of these mice showed dramatic increases in muscle mass, comparable to mice that lack myostatin entirely.

A 2010 study added a twist. Mice with only one working follistatin gene had smaller muscles that produced less force, which fits a protein that restrains myostatin. But the effect partly persisted in mice that also lacked myostatin. Follistatin was holding back something else as well, and the genetic evidence pointed to activin A.

So follistatin works as a broad release of the brakes, mopping up a family of related signals, each with jobs beyond muscle. That breadth is why it builds muscle so dramatically in mice, and also why it is hard to use safely. A drug designer would usually want the opposite, a molecule that hits one target and leaves the rest alone. Follistatin evolved to regulate a whole neighborhood of signals, and it does that wherever it travels.¹³

The mouse results are among the most striking in muscle biology. Transgenic mice making extra follistatin in muscle carried far more muscle than normal mice. A team at Nationwide Children’s Hospital in Columbus, Ohio, then used gene therapy to deliver the FS344 form to muscle and reported larger, stronger muscles in species ranging from mice to monkeys.

In those studies the team reported no organ damage and no change in reproductive capability, which addressed the FSH worry for that delivery method. The key design choice was the FS344 gene. Its product circulates in the blood instead of sticking to binding sites on cell surfaces, which the team argued limited off-target effects. Gene therapy also kept production local and continuous, so the muscle itself became the source. That design choice is easy to overlook, and it matters later, because it is the part a vial cannot copy.

The bone story is less reassuring. In a 2020 study, mice overproducing follistatin had more muscle but weaker bones and fractures, while mice lacking myostatin had more muscle and stronger bones. The difference traced to GDF11, a close relative of myostatin that helps build bone and that follistatin also blocks.¹²⁸

In the trials cited here, follistatin reached people as gene therapy, not as an injected protein. Engineered drugs built partly from follistatin are a separate line of work. In a phase 1/2a trial for Becker muscular dystrophy, an inherited muscle-wasting disease, six patients received a virus carrying the FS344 gene, injected directly into both thigh muscles. The main measure was the 6-minute walk test, how far someone can walk in six minutes.

Four of the six walked farther, by 58, 125, 108 and 29 meters. Two did not improve. Muscle biopsies showed less scarring and a more normal spread of fiber sizes, with larger fibers especially at the higher dose, and no adverse effects were reported. For a disease with no treatment at the time, the result was encouraging, and very small.

A 2017 trial in sporadic inclusion body myositis, a muscle disease that mostly begins after age 50, used the same approach in six patients along with an exercise program. Treated patients gained a median of 56 meters a year on the walk test, while an untreated comparison group declined by about 26 meters a year. Four of the six gained between 58 and 153 meters.

Not everyone accepted that reading. A researcher in Boston published a commentary in the same journal under the title Unfounded claims of improved functional outcomes attributed to follistatin gene therapy in inclusion body myositis. With six patients, an exercise program alongside and an outside comparison group, the dispute is easy to understand. Neither trial tested follistatin protein given by injection.⁴⁵⁶

The number in Follistatin-344 has a specific meaning. FS344 is the 344-amino-acid precursor encoded by one alternatively spliced follistatin transcript, in effect one edition of the recipe. When muscle reads that recipe after gene therapy, it trims off a short signal sequence and releases a 315-amino-acid protein into the blood. Researchers chose FS344 precisely because that circulating form avoids the cell-surface binding of other forms.

Now look at what is sold under that name. In 2019, a doping-control laboratory tested 17 black-market products labeled follistatin, most of them FS344. Only nine contained follistatin at all. Several of the others held different growth-promoting peptides, including MGF and GHRP-2.

The nine genuine products held a surprise. Every one contained FS344 with a His-tag, a short run of histidines that scientists attach to proteins so they can purify them in the lab, and a high share of the protein had clumped into larger complexes called oligomers. The vials looked like laboratory reagent protein built from a gene therapy sequence, then sold for injection.

This is where a hypothesis is fair to state. Gene therapy turns muscle into a local factory that keeps producing follistatin. An injected protein, tagged, partly clumped and without published human data, is a different exposure, and nothing shows it reproduces what the trials saw. Clumped and tagged proteins may also provoke the immune system, a known concern for protein drugs that has never been measured for these products.²⁷⁴

Follistatin is not the only way to block myostatin, and a related drug shows what can go wrong. ACE-031 was a fusion protein built from the ActRIIB receptor that soaked up myostatin and its relatives. In a randomized, placebo-controlled trial, it was injected under the skin of boys with Duchenne muscular dystrophy, the most common inherited muscle-wasting disease of childhood. Safety was the primary goal of the study, and the dose was raised step by step.

The trial stopped early, after the second dosing level, because of nosebleeds and telangiectasias, small dilated blood vessels in the skin. There were trends toward more lean mass, less fat, better bone density and a better-preserved walking distance, though the walking result was not statistically significant. The side effects that ended the study were not muscle-related.

The lesson carries over to follistatin. Myostatin’s relatives do other jobs. GDF11 helps build bone, and activin works in the reproductive axis. A drug that traps the family reaches those systems too, and in the case of ACE-031 the trouble appeared in blood vessels, far from the muscle it was meant to help.¹¹⁸²

No human safety data have been published for injected FS344 protein. The Becker gene therapy trial reported no adverse effects, and the inclusion body myositis report described no adverse events tied to treatment, but both used a different delivery method, in people with muscle disease, under close monitoring. Six patients per trial is also far too few to detect uncommon side effects, so even for gene therapy the safety record is only a starting point.

From the biology, three risks stand out. Follistatin suppresses FSH, so it could disturb fertility and the reproductive hormone axis. It blocks GDF11, and in mice that weakened bone. And protein products of uncertain make-up carry immune and contamination risks of their own.

The supply makes those risks harder to judge. Nearly half the black-market products in the 2019 study did not contain follistatin, and some held other growth-promoting peptides with side effects of their own. Tested athletes should also know that the His-tag lets anti-doping labs tell black-market follistatin apart from the body’s own.

Talk to a clinician first if you are pregnant, breastfeeding or trying to conceive, have a history of cancer, have low bone density, or compete in tested sport.⁴²⁸⁷

Because follistatin started life as an FSH suppressor, the reproductive hormone axis is the first thing worth checking. FSH and LH are the pituitary signals that drive the testes and ovaries. Follistatin’s effect on activin raises a fair question about FSH, though no study has set out a hormone pattern to watch for with injected FS344.

Total testosterone and estradiol add the gonad side of that picture, though estradiol in men also reflects conversion from testosterone in other tissues. Read together by a clinician, the four markers give context on the hormone axis behind muscle, libido and fertility.

Vitals Vault does not offer Follistatin-344. A clinician may order these when symptoms, history or an approach that touches the hormone system make them relevant, and they are general context, not a test that makes any compound safe. If something in the axis is already off, such as low testosterone or a high estradiol, that is usually a better place to start than a muscle-growth compound, and it can be retested to see whether a change is working.²

Follistatin-344 is not an FDA-approved drug, and it does not appear on FDA’s compounding safety page, current as of April 22, 2026. A 2019 doping-control study noted that no approved pharmaceutical formulation of follistatin was available.

The World Anti-Doping Agency lists follistatin under S4 as a myostatin-inhibiting protein, prohibited at all times, and anti-doping scientists have developed a method to detect the black-market form in urine and serum. Because the black-market protein carries a His-tag, a positive result cannot be explained away as the body’s own follistatin.¹²⁷¹³

Follistatin sits on top of one of the cleanest stories in muscle biology. Remove the myostatin brake and muscle grows, in mice and in a child born with the mutation. Follistatin is the body’s own way to ease that brake, and after gene therapy a few people with muscle disease walked farther, in trials too small to prove cause.

In one analysis of 17 black-market vials sold as follistatin, nine held a tagged laboratory protein and eight held no follistatin at all. None has human data, and follistatin’s biology raises reproductive concerns and weakened bone in mice. If muscle is your goal, the next question worth asking is which brake is actually limiting you, and whether training, protein, sleep and hormones have been measured and addressed first.¹¹⁰⁴⁷